Dawson James Securities Reiterates Speculative Buy Recommendation on Biopure Corp. (Nasdaq: BPUR) with $3.00 Price Target.

May 22, 2007, 01:00 ET from Dawson James Securities

    BOCA RATON, Fla., May 22 /PRNewswire-FirstCall/ -- Dawson James
 Securities, a full-service investment firm serving the healthcare and
 biotechnology industry, reiterated their Speculative Buy recommendation on
 Biopure Corp. (Nasdaq:   BPUR) with a 12-18 month price target of $3.00.
 Stephen M. Dunn, Director of Research, issued the report.
     The update report describes Biopure's Hemopure(R), a hemoglobin-based
 oxygen carrier, and the anticipated U.S. Navy IND submission to the FDA to
 begin the RESUS Phase II clinical trial for out-of-hospital trauma and the
 company's pending marketing authorization submission in the U.K. The report
 also highlights the significant differences between Hemopure(R) and
 competitor Northfield Laboratories (Nasdaq:   NFLD) Polyheme(R).
     Additionally, the report describes the multiple ongoing European
 clinical trials for Hemopure(R) such as the 60-patient Phase II trial in
 coronary artery bypass graft (CABG) surgery, the 100-patient Phase II trial
 in vascular disease lower limb amputation and the Phase II trial in the
 Netherlands in percutaneous coronary intervention (PCI), all of which are
 currently enrolling.
     Finally, the report describes the emerging FDA safety concerns for
 erythropoiesis stimulating agents (ESAs) in chemotherapy-induced anemia
 patients such as Amgen's (NASDAQ:  AMGN) Aranesp(R) and Epogen(R) as well as
 Johnson & Johnson's (NYSE:  JNJ) Procrit(R). Mr. Dunn states "The negative
 issues surrounding ESAs may eventually provide a new and significant future
 indication for Biopure's Hemopure(R) in treating chemotherapy-induced
 anemia patients." He notes that total sales of ESAs in 2006, for all
 indications, were over $10 billion.
     A copy of the report may be obtained by contacting Dawson James
 Securities at 561-391-5555.
     About Dawson James Securities:
     Dawson James Securities is a full service investment firm with deep
 expertise in healthcare and biotechnology and having a staff of over 50
 investment professionals providing institutional research, investment
 banking and high net worth services to our clients. More information is
 available at www.DawsonJames.com
     Dawson James has acted as an investment banker for Biopure Corp. and
 the Firm and/or its directors and employees may own securities in the
 companies and may increase or decrease holdings in the future.
     The analyst certifies that 1) all of the views expressed accurately
 reflect his personal views about any and all of the subject securities or
 issuers discussed; and 2) no part of the research analyst's compensation
 was, is, or will be directly or indirectly related to the specific
 recommendations or views expressed by the research analyst; 3) the analyst
 responsible for preparing this research report receives compensation based
 upon various factors, including total revenues of Dawson James and its
 affiliates, a portion of which is generated by investment banking
 activities and 4) the analyst and/or members of their immediate family do
 not own stock in the companies mentioned.
     Dawson James Securities
     Stephen M. Dunn, 561-208-2905
     Fax: 561-391-5757
     Dawson James Securities is a member of the National Association of
 Securities Dealers, CRD number 130645.

SOURCE Dawson James Securities